Role of EGFR mutation status in patients with advanced lung adenocarcinoma treated with pemetrexed / 中国肿瘤临床
Chinese Journal of Clinical Oncology
;
(24): 1378-1381, 2013.
Artigo
em Chinês
| WPRIM
| ID: wpr-440775
ABSTRACT
Objective:
To assess the role of EGFR mutations on pemetrexed response in patients with advanced lung adenocarcino-ma.Method:
Forty pulmonary adenocarcinoma patients with evaluable lesions were retrospectively screened .They had been treated with pemetrexed-included chemotherapy and had EGFR gene test results. The evaluation endpoints were overall response rate,disease control rate and progression free survival.Result:
No significant statistical difference was seen in overall response rate(ORR) (44.4%VS 31.8%, respectively) and disease control rate(DCR) (88.9%VS 81.8%, respectively ) between EGFR wild group and EGFR muta-tion group, but patients in EGFR wild group had longer progression free survival(PFS) ( 8.9 months VS 5.3 months;P=0.046). Conclu-sionEGFR mutation status can influence the efficacy of pemetrexed.
Texto completo:
DisponíveL
Índice:
WPRIM (Pacífico Ocidental)
Idioma:
Chinês
Revista:
Chinese Journal of Clinical Oncology
Ano de publicação:
2013
Tipo de documento:
Artigo
Similares
MEDLINE
...
LILACS
LIS